Navigation Links
Accuray Incorporated CFO Resigns
Date:9/3/2013

SUNNYVALE, Calif., Sept. 3, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today that Derek Bertocci has resigned as Senior Vice President and Chief Financial Officer of the company effective September 2, 2013.  Today, Accuray has appointed Gregory Lichtwardt, executive vice president, chief financial officer, effective immediately.  Mr. Bertocci is anticipated to continue in a consulting role with the Company.

Mr. Lichtwardt, age 59, joins Accuray after spending over nine years with Conceptus Inc., where he served as Executive Vice President, Chief Financial Officer. During his time at Conceptus Inc., its sales grew from $8 million to $141 million and adjusted EBITDA reached 20 percent of sales.

Lichtwardt brings to Accuray thirty-three years of financial and operational leadership experience in building technology companies. Prior to joining Conceptus Inc., he served as Executive Vice President, Chief Financial Officer and Corporate Secretary of Innoventry, Inc., a financial services company.  He was previously with Ocular Sciences, Inc. a world-wide developer and marketer of soft contact lenses, as Vice President, Finance and Chief Financial Officer, a company which he took public.  Prior to that, Mr. Lichtwardt held senior management positions with Allergan, Inc. and started his career with American Hospital Supply Corporation.  Mr. Lichtwardt also serves on the board of directors of Biolase, Inc., where he is the chair of the audit committee and participates on the compensation committee.

Commenting on his appointment, Mr. Lichtwardt said, "This is an exciting time to be joining Accuray.  The Company has made significant strides, is led by a talented team and is positioned to achieve significant grow
'/>"/>

SOURCE Accuray Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Healthcare Briefing - Leading Medical Companies in the News: Bio-Solutions, Catalyst Pharmaceutical, MannKind, Amgen, Accuray
2. Accuray Announces Results for Fourth Quarter and Fiscal Year 2013
3. Accuray to Host Investor Meeting at ASTRO 2013
4. Accuray to Report Financial Results for Fourth Quarter and Year End Fiscal 2013
5. Accuray is Honored for Delivering World-Class Customer Service
6. Accuray Incorporated to Present at 2013 Jefferies Global Healthcare Conference
7. Accuray Announces Results for Third Quarter Fiscal 2013
8. Accuray Incorporated to Report Financial Results for Third Quarter Fiscal 2013
9. Accuray Provides Clarification on Recently Initiated Voluntary Recalls
10. Dr. Emad Rizk Joins Accuray Board of Directors
11. Accuray Incorporated to Speak at Cowen and Company 33rd Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)...   Mast Therapeutics, Inc. (NYSE MKT: ... Santosh Vetticaden, Chief Medical Officer and Senior Vice ... reasons, in mid-September.  Edwin L. Parsley , ... which Mast acquired earlier this year, will assume ... Chief Medical Officer.  Dr. Parsley previously was with ...
(Date:8/29/2014)... Research and Markets has announced ... Market & Pipeline Insight 2014" report to their ... prevent and eradicate the prevalence of cancer have achieved ... to low specificity, safety and large number of side ... better solution. It has been discovered that peptides can ...
(Date:8/29/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) ... District of New Jersey has ... Sandoz, Inc. regarding United Therapeutics, Remodulin ® product.  In ... U.S. Patent No. 6,765,117 is both valid and enforceable ... generic product until the expiration of that patent in ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2
... off daily GERD medication at 1 year ... after transoral incisionless fundoplication surgery, REDMOND, Wash., ... natural orifice surgery products and procedures, announces,outstanding results ... patients,in the phase 2 multi-center study of the ...
... Dong-A PharmTech Co., Ltd.,announced today that its ... patient, phase 2 proof of concept clinical study ... phosphodiesterase type 5 inhibitor, for,portal hypertension, an unmet ... investigate the safety and efficacy of udenafil in ...
Cached Medicine Technology:EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study 2EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study 3EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study 4Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil 2Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil 3
(Date:8/29/2014)... Colo. (Sept. 2, 2014) A team of scientists ... reported the breakthrough discovery of a process to expand ... These findings could have implications that extend beyond cancer, ... autoimmune diseases., In an article published Aug. ... Charles C. Gates Center for Regenerative Medicine and Stem ...
(Date:8/29/2014)... 2014 LiveOps, Inc., the global leader ... announced that LiveOps has been selected as a call ... of Strength Telethon for the third year in a ... awareness to support MDA’s mission to help children and ... fatal muscle disease. This year’s program includes performances by ...
(Date:8/29/2014)... Reinberg HealthDay Reporter ... majority of American babies are getting the vaccines they ... officials said Thursday. More than 90 percent of ... and rubella (MMR); polio; hepatitis B and chickenpox (varicella), ... Prevention. "Nationally, vaccination among children 19 to 35 ...
(Date:8/29/2014)... 29, 2014 Floors of hospitals and ... wearing socks. Also, many patients are relegated to lying ... surgery recovery, Alzheimer’s, etc. Two inventors from Perrysburg, Ohio, ... patient safety. , This special pair of socks helps ... keeps patients who are relegated to beds or chairs ...
(Date:8/29/2014)... cigarettes in plain packages doesn,t increase the use of ... small stores, according to new research from Australia. ... it tried to prevent Australia from becoming the first ... tobacco products in 2012. Similar legislation is being considered ... surveyed nearly 2,000 adult smokers in Australia before and ...
Breaking Medicine News(10 mins):Health News:CU scientists' discovery could lead to new cancer treatment 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 3Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 4Health News:Most U.S. Babies Get Their Vaccines: CDC 2Health News:Most U.S. Babies Get Their Vaccines: CDC 3Health News:Study Counters Critics of Plainer Cigarette Packaging 2
... New findings from the St. Jude Children,s Research Hospital ... helped identify the mechanism that makes the childhood eye ... tumor develops so rapidly while other cancers can take ... also led investigators to a new treatment target and ...
... launched a freely available website for published research results ... University Pediatric Cancer Genome Project (PCGP). The PCGP is ... entire genomes of both normal and cancer cells from ... identify genetic mistakes that lead to childhood cancers. ...
... MADISON Placing a stent in a key artery in the ... standard surgical treatment of carotid artery disease, according to a ... Vascular Surgery . A team of researchers led ... at University of Wisconsin School of Medicine and Public Health, ...
... 11 (HealthDay News) -- Keeping an eye on Internet search ... an early warning system about potential surges in seasonal flu ... more effective than waiting for outdated government flu case reports, ... reviewed Google Flu Trends data for Baltimore and matched that ...
... laboratory tests of an imaging agent that shows promise for ... brain signs that now can,t confirm a diagnosis until ... ACS Medicinal Chemistry Letters . Masahiro Ono and ... now exists for AD, which is claiming an increasingly heavy ...
... to condescendingly, excluded from a meeting, or ignored by a ... differently depending on whether your co-worker is a man or ... incivility towards colleagues feel negative emotions especially when the ... work, by Kathi Miner from Texas A&M University and Angela ...
Cached Medicine News:Health News:Gene identified as a new target for treatment of aggressive childhood eye tumor 2Health News:Gene identified as a new target for treatment of aggressive childhood eye tumor 3Health News:St. Jude Children's Research Hospital launches data website for genome project 2Health News:Stenting for stroke prevention becoming safer in high-risk patients 2Health News:Internet Flu Searches May Warn of Outbreaks 2Health News:'I feel your pain ...' 2
... Plus Instrument for applications ... ,The VERSASTEP™ Plus ... working length is a ... utilizing radial dilation. It ...
... system device is comprised of the following ... access port are also packaged in the ... cone with 12 mm Step™ cannula assembly ... 12 mm locking cone with 10/12 mm ...
... The Step™ and Mini Step™ device components are ... Step™ Single Use System is supplied sterile in ... packaged in various configurations and combinations. They are ... Access needle and the Step™ radially Expandable Sleeve. ...
... The Premium One-Step™ single-use system device is ... ,The device components for creating each access ... configurations: , Step™ insufflation and access ... packaged separately. , Step™ radially expandable sleeve, ...
Medicine Products: